기업
Genomictree Finished $10M Investment Round for US Corporation and Has Hired CMO
by Jongwon Jang
Peter Kang, Chief Medical Officer of Promise Diagnostics, promotes clinical trials for Early Diagnosis Kit for Colorectal Cancer
Genomictree has established a local corporation in the United States in order to advance the release of its early diagnosis kit for colorectal cancer. It has also secured key personnel in order to lead local clinical trials and spearhead commercialization of the product.
Genomictree announced on 18th that it had recruited Peter Kang as Chief Medical Officer of the U.S. corporation Promise Diagnostics, Inc. Peter Kang graduated from Seoul National University College of Medicine and worked at the Roswell Park Cancer Center after receiving his training in diagnostic examination medicine and molecular genetic pathology at the University of Pittsburgh. He later earned a master's degree in Biomedical Informatics while conducting his postdoctoral studies at Stanford University in the United States.
He worked for seven years as a Laboratory General Director and a Medical Director at the Genetic Test and Genetic Counseling Company Counsel in the US, and was responsible for the clinical significance and accuracy of the tests provided to more than one million patients.
"Peter Kang has extensive experience in the US diagnostics market, including research and diagnostic product development at Stanford University and in Silicon Valley," said Ahn Sunghwan, CEO of Genomictree. "He will be in charge of conducting the USFDA clinical trials of EarlyTectⓇ, a product for the early detection of colorectal cancer."
Genomictree decided to establish Promise Diagnostics, Inc. as a corporation in the United States at the end of March, and recently secured 10 million USD (about 12 billion KRW).
Promise Diagnostics, Inc., located in Pasadena, California, will implement and support clinical trials for USFDA approval of products for the early diagnosis of colorectal cancer. It will also promote commercialization and post-contract management, and will attract foreign investment in North America. Currently, the US is pursuing a CRO contract for approval of the USFDA clinical trial.
